Without validated biomarkers of efficacy, real-world results remain anecdotal at best
"In addition, these results highlight the need for further research to elucidate potential mechanistic links between GLP-1 receptor agonist therapy, weight loss, and hair loss, and to identify patient level risk factors that may increase susceptibility to hair loss." It's worth pointing out that the medical records the researchers were dealing with were limited in terms of measuring the severity and duration of the hair loss, and whether or not it was reversible
#FunctionalMedicine #WeightLoss #Tesofensine #ObesityTreatment #MetabolicHealth To view or add a comment, sign in Breakthrough from Eli Lilly: Oral GLP-1 Drug Orforglipron : Im excited to highlight this emerging therapy that carries significant implications for the treatment of obesity and type 2 diabetes
If youre a VP or Director working in strategy or corporate development at a hospital, health system or provider organization, you will get a lot of value out of my community as I purpose-build the content, fireside chats, and conversations for this group